Trial reportDiabetologia1996
GLP-1 does not not acutely affect insulin sensitivity in healthy man.
Trial report in Diabetologia, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01159847 (Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA)
Who cites it
25 citing papers in PubMed, 116 citations in OpenAlex.
- Effects of GLP-1 Infusion Upon Whole-body Glucose Uptake and Skeletal Muscle Perfusion During Fed-state in Older Men.The Journal of clinical endocrinology and metabolism · 2023Trial
- Intermittent versus continuous enteral nutrition attenuates increases in insulin and leptin during short-term bed rest.European journal of applied physiology · 2020Trial
- Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.Journal of hepatology · 2016Trial
- Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes.Diabetes care · 2013Trial
- Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.British journal of clinical pharmacology · 2012Trial
- Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Article
- Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders.Nature aging · 2026Review
- The incretin/glucagon system as a target for pharmacotherapy of obesity.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2022 · on this mapReview
- Article
- Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.British journal of pharmacology · 2014Review
- Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?Diabetologia · 2013Article
- Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog.American journal of physiology. Endocrinology and metabolism · 2013Article
- Regulation of glucose kinetics during exercise by the glucagon-like peptide-1 receptor.The Journal of physiology · 2012Article
- Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance.Endocrinology · 2010Article
- The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.Diabetes · 2010Article
- Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats.American journal of physiology. Regulatory, integrative and comparative physiology · 2009Article
- The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action.Endocrinology · 2009Article
- Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell.Endocrinology · 2009Article
- Article
- Boc5, a non-peptidic glucagon-like Peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice.PloS one · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have suggested that glucagon-like peptide-1 (GLP-1) (7-36 amide) may have the direct effect of increasing insulin sensitivity in healthy man. To evaluate this hypothesis we infused GLP-1 in seven lean healthy men during a hyper insulinaemic (0.8 mU.kg-1.min-1), euglycaemic (5 mmol/l) clamp. Somatostatin (450 micrograms/h was infused to suppress endogenous insulin secretion, and growth hormone (3 ng.kg-1.min-1) and glucagon (0.8 ng.kg-1.min-1) were infused to maintain basal levels. GLP-1 (50 pmol.kg-1.h-1) or 154 mmol/l NaCl (placebo) was infused after 3 h of equilibration, i.e. from 180-360 min. GLP-1 infusion resulted in GLP-1 levels of approximately 40 pmol/l. Plasma glucose, insulin, growth hormone, and glucagon levels were similar throughout the clamps. The rate of glucose infusion required to maintain euglycaemia was similar with or without GLP-1 infusion (7.69 +/- 1.17 vs 7.76 +/- 0.95 mg kg-1.min-1 at 150-180 min and 8.56 +/- 1.13 vs 8.55 +/- 0.68 mg.kg-1.min-1 at 330-360 min) and there was no difference in isotopically determined hepatic glucose production rates (-0.30 +/- 0.23 vs -0.16 +/- 0.22 mg.kg-1.min-1 at 330-360 min). Furthermore, arteriovenous glucose differences across the forearm were similar with or without GLP-1 infusion (1.43 +/- 0.23 vs 1.8 +/- 0.29 mmol/l), (ANOVA; p > 0.60, in all instances). In conclusion, GLP-1 (7-36 amide) administered for 3 h, leading to circulating levels within the physiological range, does not affect insulin sensitivity in healthy man.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.